



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Application of)	
)	Group Art Unit: 1648
Pablo D. GARCIA, <i>et al.</i>)	
)	Examiner: Winkler, U.
Serial No. 10/016,604)	
)	Atty. Docket 002441.00008 (PP16466.0002)
Filed: December 7, 2001)	

For: ENDOGENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
Customer Service Window
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98 *et seq.*, enclosed is a Form PTO/SB/08b citing documents, in addition to those cited in the Information Disclosure Statement filed September 17, 2003, in the above-captioned patent application. Entry and consideration of the cited documents are respectfully requested, together with a return of the Form PTO/SB/08b initialed by the Examiner indicating the same.

These additional references are being provided within the time period specified under 37 C.F.R. § 1.97(b)(4), *i.e.*, before the mailing of a first Office Action on the merits, after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Therefore, no fee is believed to be due. However, if there is a fee, please debit our Deposit Account No. 19-0733, accordingly.


Copies of all cited references are submitted herewith.

In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed as an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to establish patentability over any of the listed references, should they be applied against the claims of the above-captioned patent application.


Respectfully submitted,

Date: July 21, 2006

By:


Benjamin C. Spehlmann
Registration No. 45,649

BANNER & WITCOFF, LTD.
1001 G Street, N.W.
Washington, D.C. 20001
Telephone: (202) 824-3000



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/016,604
Filing Date	December 7, 2001
First Named Inventor	Pablo D. GARCIA
Art Unit	1648
Examiner Name	Winkler, U.
Attorney Docket Number	002441.00008 (PP016466.002)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Counterpart PCT Application, "PCT Notification of Transmittal of the International Search Report" (May 13, 2003)	
		SAUTER, M. <i>et al.</i> , "Human Endogenous Retrovirus K10: Expression of Gag Protein and Detection of Antibodies in Patients with Seminomas," JOURNAL OF VIROLOGY, Vol. 69(1): 414-421 (Jan. 1995)	
		GOEDERT, J. <i>et al.</i> , "High Prevalence of Antibodies against HERV-K10 in Patients with Testicular Cancer but not with AIDS," CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION, Vol. 8: 293-296 (April 1999)	
		KURDYUKOV, S. <i>et al.</i> , "Full-sized HERV-K (HML-2) Human Endogenous Retroviral LTR Sequences on Human Chromosome 21: Map Locations and Evolutionary History," GENE, Vol. 273(1): 51-61 (July 2001)	
		GRIFFITHS, D., "Minireview: Endogenous Retroviruses in the Human Genome Sequence," GENOME BIOLOGY, Vol. 2(6):reviews 1017.1-1017.5 (2001)	
		TRISTEM, M., "Identification and Characterization of Novel Human Endogenous Retrovirus Families by Phylogenetic Screening of the Human Genome Mapping Project Database," JOURNAL OF VIROLOGY, Vol. 74(8): 3715-3730 (April 2000)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.